Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Great Article!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Apr 22, 2021 3:20pm
122 Views
Post# 33046670

RE:Re: Great Article!

RE:Re: Great Article!
Yellowknifer69 wrote: Hey Longs:

Someone shared this link on another board.  If anything it gives food for thought to our investing strategies!

https://www.griproom.com/fun/why-your-stock-is-always-red?fbclid=IwAR3Sf27S2jKwLKonf4bHfM0L9zLqMlu3RVPn4BKDmw6RD3lHFSXKLCuP19Q

Stay Long Boys,

Yellowknifer


Exactly Yellow.
It's easy to blame others but in the end, it's our own fear, it's our own greed and it's our thin skin that drops a stock price to these depths.
The Reddit attack on GME is what happens with the opposite attitude ... where shareholders by and hold.

You buy. And you hold. You hold forever. You never, ever sell until your thesis plays out.

I have thick skin and I'm not in the mood to buy/sell my holdings - just waiting for deals to come and for ATE to design and develop good drugs.  Whatever happens after that, I'm good with it.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities